FDA import refusal: Tirzepatide (Anti-diabetic) (United Kingdom)
FDA refuses entry of TIRZEPATIDE from the UK; verify suppliers.
What changed & why it matters
MedSpaRadar recorded an FDA import refusal at the federal level, dated July 7, 2026, in the GLP-1 Compounding category, naming TIRZEPATIDE.
An import refusal marks a shipment of TIRZEPATIDE the FDA stopped at the U.S. border as violative — the gray-market corridor a med spa must never source injectables from. Foreign, unapproved, or misbranded product refused at import is exactly what surfaces when a practice buys outside verified US-licensed 503A/503B or FDA-registered channels.
- Type
- FDA Import Refusal
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
- Substance
- TIRZEPATIDE
- Recorded
- July 7, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
The FDA record
- Firm
- ARAMEX- TRANSIT
- Origin
- Slough, United Kingdom
- Product
- Tirzepatide (Anti-Diabetic)
- FDA classification
- Human Drugs
- Refused
- Jul 7, 2026
- FDA district
- Division of Northeast Imports
- Firm FEI
- 3023423463
- FDA shipment ID
- SCS-4498917-3/10002/1
Why FDA refused it
Adulteration501(a)(2)(B), 801(a)(3); ADULTERATION
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that the methods used in and controls used for the manufacture, processing, packing, or holding of drugs and other products do not appear to conform to current good manufacturing practices within the meaning of Section 501(a)(2)(B).
FDA charge codes on this record: 27 (Adulteration). Definitions via the FDA Refusal Charges Reference.
Verify at FDA
FDA doesn’t publish a page per refusal. Open the FDA Import Refusals database and search by shipment ID SCS-4498917-3/10002/1 (or firm FEI 3023423463), refused Jul 7, 2026.
FDA Import Refusal · FDA Import Refusals database ↗FDA record · ARAMEX- TRANSIT · Slough · drug product · refused as adulteration
Related alerts
- FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
- FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
- FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
- FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA recall (Class II): Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, Co 80…
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.